增殖诱导配体 (APRIL) 是肿瘤坏死因子 (TNF) 细胞因子超家族的关键成员，在 B 细胞存活、增殖和免疫球蛋白类别转换中发挥核心作用。最近，由于 APRIL 和相关细胞因子 B 细胞激活因子 (BAFF) 在多种肾小球疾病中的作用，人们越来越关注它们在上述过程中的重要性。 APRIL 的治疗性抑制代表了一种潜在有吸引力的免疫调节方法，与 B 细胞耗竭策略相比，它可以消除自身免疫性疾病中有害的宿主免疫反应，同时保持体液免疫的其他重要功能完整，例如记忆 B 细胞功能和对疫苗接种的反应。在这篇综述中，我们描述了 APRIL 在 B 细胞发育中的生理作用及其与肾小球疾病的相关性，并概述了研究 APRIL 抑制的新兴临床试验数据，重点是 IgA 肾病，其中 APRIL 抑制剂的临床开发处于最先进的阶段stage.版权所有 © 2024。由 Elsevier Inc. 出版。

A PRoliferation Inducing Ligand (APRIL) is a key member of the tumor necrosis factor (TNF)-superfamily of cytokines, and plays a central role in B cell survival, proliferation and immunoglobulin class switching. Recently, there has been increasing interest in the role of APRIL and the related cytokine B cell activating factor (BAFF) in several glomerular diseases, due to their importance in the above processes. The therapeutic inhibition of APRIL represents a potentially attractive immunomodulatory approach, that may abrogate deleterious host immune responses in autoimmune diseases while leaving other important functions of humoral immunity intact, such as memory B cell function and responses to vaccination, in contrast to B cell depleting strategies. In this review, we describe the physiological roles of APRIL in B cell development and their relevance to glomerular diseases, and outline emerging clinical trial data studying APRIL inhibition, with a focus on IgA nephropathy where the clinical development of APRIL inhibitors is in its most advanced stage.Copyright © 2024. Published by Elsevier Inc.